Blueprint Medicines Corporation

Steven Mark Wenglowsky

Joseph L Kim

Chandrasekhar V Miduturu

Neil Bifulco

Natasja Brooijmans

Douglas Wilson

Yulian Zhang

Lucian V DiPietro

Brian Lewis Hodous

Paul E Fleming

Philip D Ramsden

Richard Vargas

The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

CDK2 inhibitors

This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.

Compounds and compositions useful for treating disorders related to NTRK

This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I): 

Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g., for treating a condition mediated by aberrant RET activity 

2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors

This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula I: 

Compounds and compositions useful for treating disorders related to Kit are described herein.

Growing community of inventors

Cambridge, MA, United States of America

Steven Mark Wenglowsky